The recurrence rate (crude incidence per 1000 PY) for intracranial tumors in GH-treated GeNeSIS patients was 8.1% (19.4%) overall, and 13.7% (29.9%) and 2.8% (8.5%) for craniopharyngioma and medulloblastoma, respectively. This evidence concerns the gene GH1 and craniopharyngioma.